Yuhan recovers license for its non-small cell lung cancer therapy from Luoxin
Yuhan Corporation cancelled the technology export agreement of a targeted therapy for non-small cell lung cancer, YH25448, with a Chinese pharmaceutical company Luoxin Biotechnology.
According to Yuhan Coporation, the company made a technology export and co-development agreement of YH25448 for t...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
